Proceedings of the 2nd International Conference on Contemporary Science and Clinical Pharmacy 2021 (ICCSCP 2021)

Mortality of Hemodialysis Patients with Comorbidities at RSUP Prof Dr R.D Kandou, Manado, North Sulawesi

Authors
Stefanus Lukas1, 2, *, Diana Laila Ramatillah1, Apricia Latuharhary1, Yufri Aldi2, Fatma Sri Wahyuni2
1Faculty of Pharmacy, Universitas 17 Agustus 1945 Jakarta, Jakarta Utara, Indonesia
2Faculty of Pharmacy, Universitas Andalas, Padang Indonesia
Corresponding Author
Stefanus Lukas
Available Online 17 November 2021.
DOI
10.2991/ahsr.k.211105.027How to use a DOI?
Keywords
Chronic kidney disease; comorbid conditions; Hemodialysis; Mortality
Abstract

Background: Hemodialysis is a process in renal replacement function. Comorbid is one of the contributing factors for the high mortality among hemodialysis patients. Objective: To determine the correlation between comorbidities and duration of HD treatment and the effect of HD treatment duration on mortality rates in chronic kidney disease mortality patients undergoing hemodialysis. Methods: A retrospective cohort study was conducted in this study. This study included Hemodialysis patients with comorbid HD patients (DM, Hypertension and Congestive Heart disease) who died in 2018. The HD population was 560 patients (n=84) using convenience sampling method. The analysis was carried out using the Chi Square test and the Kruskall Wallis and Mann-Whitney test. Certificate of Ethical Eligibility from the Health Research Ethics Committee of RSUP DR R.D Kandou Manado no: 064/EC/KEPK-KANDAU/VII/2020. Results: The results of treatment were of 0-24 months (40.5 %), 25-48 months (33.3%) and > 48 months (26.2 %). The analysis showed a significant correlation between the duration of HD treatment and comorbidities in CKD patients undergoing HD, namely comorbid DM after HD (p=0.002), hypertension after HD (p=0.010), congestive heart failure after HD (p=0.003), with 2 comorbidities (p=0.048), and 3 comorbidities (p=0.011). Besides, the effect of the duration of HD treatment on the mortality rate is known that the duration of treatment >48 months gives a lower mortality rate with an average treatment time of 360 days. Conclusion: HD patients with the duration of treatment of 0-12 months died the most than the duration of treatment >25- 48 months. There was a significant correlation between Comorbid-3 and the duration of HD treatment in CKD patients (p=0.011).

Copyright
© 2021 The Authors. Published by Atlantis Press International B.V.
Open Access
This is an open access article under the CC BY-NC license.

Download article (PDF)

Volume Title
Proceedings of the 2nd International Conference on Contemporary Science and Clinical Pharmacy 2021 (ICCSCP 2021)
Series
Advances in Health Sciences Research
Publication Date
17 November 2021
ISBN
978-94-6239-450-6
ISSN
2468-5739
DOI
10.2991/ahsr.k.211105.027How to use a DOI?
Copyright
© 2021 The Authors. Published by Atlantis Press International B.V.
Open Access
This is an open access article under the CC BY-NC license.

Cite this article

TY  - CONF
AU  - Stefanus Lukas
AU  - Diana Laila Ramatillah
AU  - Apricia Latuharhary
AU  - Yufri Aldi
AU  - Fatma Sri Wahyuni
PY  - 2021
DA  - 2021/11/17
TI  - Mortality of Hemodialysis Patients with Comorbidities at RSUP Prof Dr R.D Kandou, Manado, North Sulawesi
BT  - Proceedings of the 2nd International Conference on Contemporary Science and Clinical Pharmacy 2021 (ICCSCP 2021)
PB  - Atlantis Press
SP  - 189
EP  - 193
SN  - 2468-5739
UR  - https://doi.org/10.2991/ahsr.k.211105.027
DO  - 10.2991/ahsr.k.211105.027
ID  - Lukas2021
ER  -